Debt-to-equity of Sigyn Therapeutics, Inc. from 30 Jun 2016 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Sigyn Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2016 to 30 Sep 2025.
  • Sigyn Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -103%, a 5.6% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Sigyn Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -103% +6.2% +5.6% 30 Sep 2025
Q2 2025 -105% +4.2% +3.9% 30 Jun 2025
Q1 2025 -107% +2.8% +2.6% 31 Mar 2025
Q4 2024 -108% +6% +5.3% 31 Dec 2024
Q3 2024 -109% +6.8% +5.8% 30 Sep 2024
Q2 2024 -109% +9.8% +8.2% 30 Jun 2024
Q1 2024 -110% +14% +12% 31 Mar 2024
Q4 2023 -114% +14% +11% 31 Dec 2023
Q3 2023 -116% +33% +22% 30 Sep 2023
Q2 2023 -119% +145% +55% 30 Jun 2023
Q1 2023 -124% -1378% -110% 31 Mar 2023
Q4 2022 -128% -507% -134% 31 Dec 2022
Q3 2022 -149% -399% -160% 30 Sep 2022
Q2 2022 -264% -851% -145% 30 Jun 2022
Q1 2022 1253% +2125% 31 Mar 2022
Q4 2021 380% +1990% 31 Dec 2021
Q3 2021 250% +1489% 30 Sep 2021
Q2 2021 586% +862% 30 Jun 2021
Q1 2021 -872% -709% -435% 31 Mar 2021
Q4 2020 -1610% -1489% 31 Dec 2020
Q3 2020 -1239% -1118% -920% 30 Sep 2020
Q2 2020 -276% -144% -110% 30 Jun 2020
Q1 2020 -163% +74% +31% 31 Mar 2020
Q4 2019 -121%* +163% 31 Dec 2019
Q3 2019 -122% +251% +67% 30 Sep 2019
Q2 2019 -131% 30 Jun 2019
Q1 2019 -237% 31 Mar 2019
Q4 2018 -284% 31 Dec 2018
Q3 2018 -372% 30 Sep 2018
Q3 2016 -282% 30 Sep 2016
Q2 2016 -428% 30 Jun 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.